Thanks, Alan. Before discussing overall market developments, I'd like to provide an update on the properties we previously disclosed last quarter where tenants Parallel and Green Peak have not paid rent. As we noted then and I think it is worth repeating here, we are of course first and foremost focused on maximizing the value of each of our properties and having tenants with strong teams that can manage their businesses successfully through inevitable ups and downs of this industry. We have engaged local counsel and other advisors in these situations, commence legal proceedings for damages and possession and are in discussions with applicable regulatory agencies. With our veteran team internally in combination with our advisors across a spectrum of specialties, I am confident in our ability to successfully navigate these situations. As noted during our prior earnings call, we commenced litigation against Green Peak at our Summit property in Michigan. In early March, as many of you may know Green Peak was placed into receivership and in mid-March we regained possession of the Summit building. In addition, we regained possession of two small retail locations in Michigan previously leased to Green Peak for which our total investment is less than $3 million. Receivers paying rent on all other remaining properties leased to Green Peak including the harvest part cultivation and processing facility and four other retail locations. And we are closely monitoring the situation and receivership process. We are currently in the process of discussing and touring the Summit property with interested cannabis operators. As noted in our prior call, we also filed actions against Parallel for possession and damages at our Pennsylvania property and our Texas property, which is in the early stages of development. We regained possession of the Texas property in mid-March, where Parallel failed to pay rent for the first time in February. We are actively exploring all options for these properties including speaking to a number of interested parties. As we noted previously, Parallel is current on the other two properties, we leased to them in Florida. And for Kings Garden, they continue to pay rent at the four properties they occupy and continue to explore a potential merger transaction. Market developments. While it is clear that the regulated cannabis industry has experienced in the past several months and continues to experience a set of challenging circumstances. I would like to note that the growth of the overall cannabis industry in the United States is expected to continue to be strong. With industry research group, New Frontier Data projecting a doubling of annual sales from 2023 to 2030 to over $70 billion, representing a double-digit compound annual growth rate. The regulated cannabis industry remains an exceptional case of industry size and growth potential. As we've noted for some time now, unit pricing for regulated cannabis products have been challenged in certain states at the wholesale level, reflective of what we believe to be a number of factors including basic supply/demand dynamics, lack of meaningful enforcement in certain states on illicit, non-licensed cannabis sales by state and local enforcement authorities, taxation and general macroeconomic conditions. Reflecting that continued price compression in combination with the continued inflation on input and labor costs. We note that consensus, analyst expectations for 2023 EBITDA have fallen significantly for publicly traded U.S. operators nearly across the board. That said, this price compression dynamic is certainly not uniform across states and we are cautiously optimistic that certain states like California may have turn the corner on the persistency of unit pricing declines, while new adult use states like Missouri are seeing very healthy wholesale pricing dynamics. Capital availability. Another continuing theme from our prior calls is the tightening of financial conditions and the impact it continues to have on capital availability for the cannabis industry. As with other industries, the cost of capital and capital availability have fundamentally changed for cannabis operators over the course of the past year or so. As we noted previously, capital raising across the cannabis industry continues to be very subdued with rating and capital advisors reporting that U.S. operator capital raises were down 86% in Q1 versus the prior year period and of those raises nearly 90% was in the form of debt. From our perspective, we believe the present macroeconomic challenges of unit pricing, compression and cost inflation in combination with depressed valuations and capital availability have translated into the larger MSOs focusing more on efficiency of existing operations and generating positive free cash flow versus growth through M&A, that certainly appear to be the case in Q1 of this year, where we saw a little over $815 million in M&A transactions versus over $2.5 billion from Q1 of last year. State programs. Shifting to state-specific programs, as noted in prior calls, we continue to see momentum in states that span the political spectrum. Missouri officially launched its adult-use program in February with regulated cannabis sales in March totaling over $126 million alone. Maryland's adult-use program is also expected to see first legal sales in July 1st, and just last month, Delaware became the 22nd state to legalize adult-use cannabis. Meanwhile, adult-use legislation is progressing through the Minnesota Legislature and there are expectations that Ohio and Pennsylvania could legalize adult-use cannabis this year. Federal legislation. On the federal legislation front, as you know versions of the SAFE Act were introduced again in both the House and Senate late last month. There are some reasons to be optimistic on potential passage. One this bicameral push on its face appears to signal that this legislation could be a priority. Two, a version of SAFE has passed the House seven times now and three, the Senate Bill has 40 total sponsors, including seven Republicans. That said, as we have stated for years now, getting a version of this bill through the process and into law continues to be daunting and will require significant time spent by Congress and an alignment of numerous sets of competing interests. We also want to note some of the recent commentary by federal officials and commercial organizations, which we believe show the continued momentum forward for change. In late March, the Wine and Spirits Wholesalers of America issued a letter to Congress calling for cannabis to be regulated on the federal level like alcohol advocating for comprehensive federal legalization. Also in March, U.S. Health and Human Services Secretary, Xavier Becerra provided an update on his agency's role and status of the ongoing cannabis scheduling review and while not providing a definitive timeline for completion of the review, did note the process will take into account shifts and what cannabis means to Americans over the last several decades. Also last month in testimony to the Senate, Attorney General Merrick Garland provided an update on the DOJ's potential establishment of a Cole memo 2.0. While the timing and scope of federal reform continues to be uncertain, we see the reintroduction of the SAFE Act in both the House and Senate and these positions has incrementally positive steps in the road to reform. I'd like to now turn the call over to Ben to discuss our investment and portfolio activity in the first quarter and year-to-date. Ben?